Literature DB >> 26666838

Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein.

N L Rey1, S George1, P Brundin1.   

Abstract

Synucleinopathies are characterized by abnormal proteinaceous aggregates, mainly composed of fibrillar α-synuclein (α-syn). It is now believed that α-syn can form small aggregates in a restricted number of cells, that propagate to neighbouring cells and seed aggregation of endogenous α-syn, in a 'prion-like manner'. This process could underlie the stereotypical progression of Lewy bodies described by Braak and colleagues across different stages of Parkinson's disease (PD). This prion-like behaviour of α-syn has been recently investigated in animal models of PD or multiple system atrophy (MSA). These models investigate the cell-to-cell transfer of α-syn seeds, or the induction and spreading of α-syn pathology in transgenic or wild-type rodent brain. In this review, we first outline the involvement of α-syn in Lewy body diseases and MSA, and discuss how 'prion-like' mechanisms can contribute to disease. Thereon, we debate the relevance of animal models used to study prion-like propagation. Finally, we review current main histological methods used to assess α-syn pathology both in animal models and in human samples and their relevance to the disease. Specifically, we discuss using α-syn phosphorylated at serine 129 as a marker of pathology, and the novel methods available that allow for more sensitive detection of early pathology, which has relevance for modelling synucleinopathies.
© 2015 British Neuropathological Society.

Entities:  

Keywords:  Braak staging; Lewy bodies; Parkinson's disease; alpha-synuclein; cell-to-cell transfer; multiple system atrophy; pathology spreading; phosphorylated alpha-synuclein; prion-like; propagation

Mesh:

Substances:

Year:  2016        PMID: 26666838     DOI: 10.1111/nan.12299

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  29 in total

Review 1.  Is Braak staging valid for all types of Parkinson's disease?

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2018-06-25       Impact factor: 3.575

Review 2.  How strong is the evidence that Parkinson's disease is a prion disorder?

Authors:  Patrik Brundin; Jiyan Ma; Jeffrey H Kordower
Journal:  Curr Opin Neurol       Date:  2016-08       Impact factor: 5.710

Review 3.  α-Synuclein: Multiple System Atrophy Prions.

Authors:  Amanda L Woerman; Joel C Watts; Atsushi Aoyagi; Kurt Giles; Lefkos T Middleton; Stanley B Prusiner
Journal:  Cold Spring Harb Perspect Med       Date:  2018-07-02       Impact factor: 6.915

Review 4.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

5.  Neuromolecular imaging, a nanobiotechnology for Parkinson's disease: advancing pharmacotherapy for personalized medicine.

Authors:  P A Broderick; L Wenning; Y-S Li
Journal:  J Neural Transm (Vienna)       Date:  2016-10-28       Impact factor: 3.575

Review 6.  Multiple system atrophy: pathogenic mechanisms and biomarkers.

Authors:  Kurt A Jellinger; Gregor K Wenning
Journal:  J Neural Transm (Vienna)       Date:  2016-04-20       Impact factor: 3.575

7.  Critical appraisal of pathology transmission in the α-synuclein fibril model of Lewy body disorders.

Authors:  Negin Nouraei; Daniel M Mason; Kristin M Miner; Michael A Carcella; Tarun N Bhatia; Benjamin K Dumm; Dishaben Soni; David A Johnson; Kelvin C Luk; Rehana K Leak
Journal:  Exp Neurol       Date:  2017-10-19       Impact factor: 5.330

Review 8.  Alpha-Synuclein Toxicity on Protein Quality Control, Mitochondria and Endoplasmic Reticulum.

Authors:  Thaiany Quevedo Melo; Sjef J C V M Copray; Merari F R Ferrari
Journal:  Neurochem Res       Date:  2018-10-28       Impact factor: 3.996

Review 9.  Prying into the Prion Hypothesis for Parkinson's Disease.

Authors:  Patrik Brundin; Ronald Melki
Journal:  J Neurosci       Date:  2017-10-11       Impact factor: 6.167

10.  Brazilin Removes Toxic Alpha-Synuclein and Seeding Competent Assemblies from Parkinson Brain by Altering Conformational Equilibrium.

Authors:  George R Nahass; Yuanzi Sun; Yong Xu; Mark Batchelor; Madeleine Reilly; Iryna Benilova; Niraja Kedia; Kevin Spehar; Frank Sobott; Richard B Sessions; Byron Caughey; Sheena E Radford; Parmjit S Jat; John Collinge; Jan Bieschke
Journal:  J Mol Biol       Date:  2021-02-19       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.